ClinicalTrials.gov
public full text
Public Domain
Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation
diabetes-mellitusendocrine-system-diseasesgraftmonoclonal-antibodytype-1type-1-diabetestype-1-diabetes-mellitus
This study will evaluate the safety, tolerability and efficacy of AT-1501 in an immunomodulation regimen in adult patients with T1D undergoing an islet cell transplant.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Thymoglobuline in Non-myeloablative Allogeneic Stem-cell Transplantation#1212956
- Anti-viral Action Against Type 1 Diabetes Autoimmunity#1338611
- A Study of IMC-TR1 in Participants With Advanced Solid Tumors#1161661
- A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies#1196143
- Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis#1292736
Record · ID 1196269
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive